POZLife: Life from the Infected and Effected point of veiw.

Archive for the ‘POZ Pages’ Category

A Father’s Appeal: Choose To Act

Posted by pozlife on July 18, 2007


by Dennis Shepard

When my son Matthew was murdered nearly nine years ago, my family had a decision to make.
We could mourn Matthew’s death privately – withdrawing into some semblance of seclusion, try to resume our “normal” lives, pretending that nothing had changed…or we could use this tragedy to talk about hate and help make Matthew’s murder a wake-up call throughout our country. We made our decision – a choice we consciously and proudly continue to support every day.
Our son died because of hate. He was killed simply because he was gay. For us, our choice was a no-brainer. Not a day goes by that I don’t think about Matthew – his spirit, his passion for people, or his smile. And since his death, we have witnessed more acts of hate, bigotry, and injustice against other lesbian, gay, bi-sexual, transgender (LGBT) Americans. For Matthew and all of the other victims, our family has chosen to fight and to act – to speak out against hate, to “come-out” as allies, and to engage ourselves in the process of change.
Some days are harder than others, but I choose to act for the memory of my son. I choose to act for the memories of the thousands of victims of hate crimes. I choose to act for those that don’t have the strength or ability to act. I choose to act because we, as a nation, cannot afford not to.
I choose to act because I was, and still am, very proud of my son…of who he was and the struggles he had to overcome to become that man. I choose to act because I never want another LGBT American to go through the fear, the pain, the violence, or the loneliness that Matthew went through on that horrible night.
I choose to act because I never want another parent to go through what we went through – the grief, the giant hole in the heart, the bedside vigil, or the realization that holidays, family vacations, and the normal, dull routine of work, home, and life will never, ever be the same.
All of us – gay and straight alike – need to act. Hate affects each and every one of us. It knows no limits, follows no clear set of rules, and has infiltrated our society’s most basic institutions. For that reason, I am humbled that the United States House of Representatives has chosen to act, and to do so in Matt’s memory, and the United States Senate is poised to follow. They are now taking the first giant steps in making the Matthew Shepard Act the law of our land.
The legislation is simple: to protect people from being attacked, beaten, brutalized, and murdered because of who they are. It’s a necessary, measured response to the consequences of hate that took my son away from me and has taken far too many other Americans from those who loved them.
I challenge all of you to follow the example of the House by making the choice to act. Encourage your Senators to vote for the Matthew Shepard Act. Today. Tell your story about how hate has affected your family. Today. Come out as LGBT and allied. Today. Choose to erase hate. Today! We all have a responsibility to act. If we don’t – who will?
To find out how to contact your senators, please visit www.MatthewShepard.org.

Source: Gay Writers from 365Gay.com


Posted in POZ Pages | Leave a Comment »

Study Examines Role Of Religion In HIV Transmission

Posted by pozlife on April 29, 2007


by 365Gay.com Newscenter Staff

Posted: April 28, 2007 – 5:00 pm ET 

(New York City) HIV-positive people who say religion is an important part of their lives are likely to have fewer sexual partners and engage in high-risk sexual behavior less frequently than other people with the virus that causes AIDS, according to a new study issued by the Rand Corporation.

As a result, people with HIV who have stronger religious ties are less likely to spread the virus, according to the study by the nonprofit research organization.

The study measured religiosity by asking people to report how important religion was in their lives; whether they identified with a particular religious group; whether they preferred being with people of the same religion; and how often they attended religious or spiritual services.

David Kanouse, a Rand senior behavioral scientist and principal investigator on the project, said in a statement by group, that the study did not identify what specific component of religiosity made a difference in sexual activity. However, he said said two factors – moral beliefs and membership in a faith community – may be important.

“Moral beliefs may indicate an underlying altruism and a desire to make sure no one else is infected with HIV,” Kanouse said. “Promoting these feelings could then be used as a component of HIV prevention programs.”

“These are some significant findings about the role of religiosity in the lives of people who are HIV-positive,” said Frank H. Galvan, lead author of the study and assistant professor in the Department of Psychiatry and Human Behavior with the Charles R. Drew University of Medicine and Science in Los Angeles. “The next step is to find out how can we use this information in a way that can help lower the rate of spreading HIV to others.”

Religion remains a dominant force in America today, but the main focus of many faith communities is sexual abstinence, rather than examining how else religious beliefs may help to prevent the spread of HIV, Galvan said.

“This study suggests that there’s a role for religious institutions to play in the fight against the spread of HIV,” Galvan said. “They have these core belief systems that do have a positive impact on the lives of people who are HIV-positive and who are sexually active. Religiosity is an untapped resource in the whole struggle against HIV and AIDs, and should be looked at more thoroughly.”

Researchers studied a nationally representative sample of 1,421 people getting medical care for HIV — 932 of whom reported recent sexual activity.

Catholics were less likely than other mainline Christians, non-Christians and non-religious people to report unprotected sex. Catholics also were less likely to report high-risk sex than other mainline Christians and reported fewer partners than non-Christians.

There was no statistical difference between Evangelicals and Catholics in reported sexual activity. Evangelicals were as likely as Catholics to have fewer sexual partners, and equally likely to engage less frequently in unprotected and high-risk sex.

The RAND Health study is titled “Religiosity, Denominational Affiliation and Sexual Behaviors among People with HIV in the U.S.” It appears in the February issue of the Journal of Sex Research, which was published in March. The study was conducted with a grant from the National Institute of Child Health and Human Development and the National Institute on Alcohol Abuse and Alcoholism.

The new report used data from the HIV Cost and Services Utilization Study, which was conducted by Rand from January 1996 to April 1997, with follow-up interviews from December 1996 through June 1997. What makes this data set unique is that it was collected from a national probability sample — not race- or gender-specific — and remains the only national probability sample of HIV-positive patients in care.

Galvan said the Rand study’s findings are not likely to have changed over time. He said the findings are consistent with other studies that have found a link between religiosity and fewer lifetime sexual partners and an inverse relationship between religiosity and other high-risk behaviors, such as substance abuse.

Other studies have found that gay men report a similar rate of attendance at religious services as male heterosexuals, and about the same rate in the frequency of prayer as do female heterosexuals. African-Americans, who have been disproportionately affected by HIV/AIDS, also report high levels of both attendance at religious services and prayer.

HCSUS survey respondents were given a choice among 46 denominational affiliations, as well as the categories of agnostic/atheist, no religious preference, or having a religious preference not mentioned on the list provided. Those affiliations were then grouped into the following categories: Catholic, Evangelical, Other Christian, Non-Christian Religion, and No Religion/Agnostic/Athiest.

The Rand study found several religious differences between the survey group and the general U.S. population. The survey group appeared to be more likely to be Evangelical and more likely to be nonreligious, but less likely to come from Christian religions other than Evangelical or Catholic.

Some of these differences may be explained by the racial makeup of the survey population. African-Americans made up nearly a third of the survey population — compared with 13 percent of the U.S. population — and are more likely to belong to Evangelical denominations. Another factor influencing the high number of non-religious respondents is the fact that many religious groups consider homosexuality to be morally unacceptable. Gay and bisexual men made up more than half of the study population, Rand said.

The researchers said they don’t understand why there were differences between the different denominations, including why Catholics were more likely to use condoms despite the Catholic Church’s prohibition on birth control, but said it was a point worthy of additional research and further exploration by faith-based communities.

Other studies also have found differences between denominations in people’s sexual attitudes and behavior, often depending on which sources each denomination looks to for moral decision-making. Some Christian denominations rely solely on the Bible, while others allow for additional guidance from other sources, such as other church traditions or one’s personal conscience.

“Although the Pope may issue a proclamation on some aspect of sexual behavior, Catholics increasingly are inclined to consider their individual consciences as sources of moral authority,” the study notes. “What role this may play in the sexual behaviors of Catholics and how this may differ from other religious groups warrants further investigation.”

Posted in POZ Pages | Leave a Comment »

Treatment News : Natural Molecule in Blood Blocks HIV – by Tim Horn

Posted by pozlife on April 24, 2007


A new paper published in the journal Cell indicates that researchers have isolated yet another natural ingredient in human blood that effectively blocks the binding of HIV to CD4 cells. This latest discovery, reported by a team of scientists from a variety of institutes in Germany and at The New York Blood Center, could lead to the development of yet another class of antiretrovirals with activity against HIV resistant to approved agents.

For many years, researchers have suggested that a variety of molecules in human blood can inhibit HIV. Until recently, however, the hunt for the natural compounds with the greatest anti-HIV activity has not produced fruitful results.

To look more closely for these circulating molecules, the German and American group of academic, public health, and pharmaceutical researchers sifted through a comprehensive library of small peptides – protein fragments – that had been filtered from the blood of patients with chronic kidney failure during dialysis. After sorting through more than one million blood peptides, including several with HIV activity, the scientists ended up focusing on one that appeared to block HIV without toxic effects on cells.

The research team found that a fragment of a relatively abundant blood molecule, dubbed virus-inhibitory peptide (VIRIP), acts as a broad-based inhibitor of HIV. Laboratory studies suggested that VIRIP specifically targets a conserved region in the HIV transmembrane glycoprotein known as “gp41 fusion peptide.” This peptide, which is normally buried in the viral envelope, becomes exposed during the process of viral entry and makes the first direct contact between the viral particle and host cell.

As with the development of other compounds designed to inhibit HIV fusion and entry, VIRIP’s unique mechanism should ultimately allow it to remain effective against HIV strains resistant to many antiretrovirals currently available (and possibly other fusion/entry inhibitors).

The researchers reported that, in test tube studies, HIV does not easily develop resistance to VIRIP. There was also evidence to suggest that some derivatives of the peptide are highly stable in human blood plasma and are nontoxic even at exceedingly high concentrations.

“Our data support the possibility that VIRIP may contribute to controlling HIV-1 replication in infected individuals and that derivates thereof are highly suitable for development of a new class of HIV-1 inhibitors targeting the highly conserved gp41 fusion protein,” the researchers concluded.


Münch J, Ständker L, Adermann K, et al. Discovery and optimization of a natural HIV-1 entry inhibitor targeting the gp41 fusion peptide. Cell 129:263-75, 2007.

Source: POZ – Treatment News : Natural Molecule in Blood Blocks HIV – by Tim Horn

Posted in POZ Pages | Leave a Comment »

Equally Speaking

Posted by pozlife on March 6, 2007

Tuesday, March 6, 2007

First up on HRC’s daily webcast, the GLBT community loses a hero. Bob Hattoy broke new ground in the fight to combat HIV and AIDS in his prime-time speech on the disease at the 1992 Democratic Convention. Bob passed away over the weekend but will always be remembered for the way he changed how millions of Americans viewed people living with HIV/AIDS.

Turning to some state news, Iowa Governor Chet Culver signed a strong anti-bullying bill into law yesterday. After a tumultuous path through the Legislature, students are now protected from bullying in schools based on sexual orientation, gender, race and age.

Last year the Arkansas Supreme Court ruled that the state’s ban on gay and lesbian foster parents was unconstitutional. Now a state lawmaker has introduced a bill to ban any gay or lesbian person from serving as a foster or adoptive parent even if they are related to the child. Perhaps showing it’s not just gay people he doesn’t like, the bill would ban unmarried, cohabitating straight people from adopting or fostering unless they are related to the child.

The New York City Council’s lesbian speaker Christine Quinn is heading to Dublin this St. Patrick’s Day to march in their parade there. Organizers of New York’s parade bar GLBT people from marching openly and Quinn will continue her tradition of boycotting the New York event.

The church of Reverend Ted Haggard has seen its contributions fall significantly since Haggard stepped down amid allegation of drug use and relations with a male escort. Forty-four people have been laid off – 12 percent of the 14,000-member church’s staff.

Finally, Sydney, Australia’s famed Gay and Lesbian Mardi Gras wrapped up this week. The parade, with 8,000 participants and 120 floats, drew more than 350,000 spectators.

Posted in POZ Pages | Leave a Comment »

Group challenges feds on medical pot – Yahoo! News

Posted by pozlife on March 3, 2007


By LISA LEFF, Associated Press Writer Wed Feb 21, 2:27 PM ET

OAKLAND, Calif. – Armed with a new study showing the drug can ease pain in some HIV patients, medical-marijuana advocates sued the federal government Wednesday over its claim that pot has no accepted medical uses.

The lawsuit, filed in federal court by Americans for Safe Access, accuses the government of arbitrarily preventing “sick and dying persons from seeking to obtain medicine that could provide them needed and often lifesaving relief.”

The Food and Drug Administration‘s position on medical marijuana “is incorrect, dishonest and a flagrant violation of laws requiring the government to base policy on sound science,” Joe Elford, said chief counsel for Americans for Safe Access.

California is one of 11 states that have made marijuana legal for people with a doctor’s recommendation. But because the U.S. government does not recognize pot’s medical benefits, patients can still be arrested by federal authorities.

Last week, researchers from the University of California at San Francisco reported in the journal Neurology that a test involving 50 HIV patients showed that those who smoked pot experienced much less pain than those given placebos

Source: Group challenges feds on medical pot – Yahoo! News

Posted in POZ Pages | Leave a Comment »

India: Repeal Colonial-Era Sodomy Law (Human Rights Watch, 11-1-2006)

Posted by pozlife on March 3, 2007


India: Repeal Colonial-Era Sodomy Law

Entrapment, Arrests Harm AIDS Prevention Efforts

(Delhi, January 11, 2006) – New arrests of gay men in Lucknow, India—the scene of a case in 2001 that drew worldwide protests—show that India’s colonial-era sodomy law continues to threaten human rights and encourage the spread of HIV, Human Rights Watch said today in a letter to Prime Minister Dr. Manmohan Singh.

" Lucknow police have a shameful record of harassing gay men as well as non-governmental organizations that work with them. They are able to do so because India’s government clings to the criminalization of homosexual conduct, which only prevents people from coming forward for HIV/AIDS testing, information, and services. "

Scott Long, director of Human Rights Watch’s Lesbian, Gay, Bisexual, and Transgender Rights Program

Related Material

Epidemic of Abuse: Police Harassment of HIV/AIDS Outreach Workers in India
Report, June 1, 2002

Country Page

Thematic Page

Letter to Indian Prime Minister Singh
Letter, January 11, 2006

Free Email Newsletter

Contribute to Human Rights Watch

On January 4, Lucknow police arrested four men on charges of operating a “gay racket” on the Internet, as well as of engaging in “unnatural” sex. Police claim they seized the men while having a picnic in a public place, and accused them of belonging to an “international gay club” centered around the Internet website guys4men.com, on which gay men can place personals and engage in Internet chat. Reports received by Human Rights Watch indicate that undercover police, posing as gay on the website, entrapped one man, then forced him to call others and arrange a meeting where they were arrested.  
“Lucknow police have a shameful record of harassing gay men as well as non-governmental organizations that work with them,” said Scott Long, director of Human Rights Watch’s Lesbian, Gay, Bisexual, and Transgender Rights Program. “They are able to do so because India’s government clings to the criminalization of homosexual conduct, which only prevents people from coming forward for HIV/AIDS testing, information, and services.”  
In July 2001, Lucknow police, apparently spurred by an informer, raided the local offices of two nongovernmental organizations (NGOs) working on HIV/AIDS prevention, the Naz Foundation International (NFI) and Bharosa Trust. Four staff members were jailed for 47 days in deplorable conditions, accused of running a gay “sex racket.” Police declared the HIV/AIDS-related information materials seized in the raided offices “obscene.” They charged the men under India’s sodomy law, criminal conspiracy, aiding and abetting a crime and the sale of obscene materials. After international condemnation of the detention of the “Lucknow Four,” the case was eventually dropped.  
In a 2002 report, Epidemic of Abuse, Human Rights Watch documented how India’s sodomy law has been used to harass HIV/AIDS prevention efforts, as well as sex workers, men who have sex with men, and other groups at risk of the disease. Section 377 of the Indian Penal Code, titled “Of Unnatural Offences,” punishes “carnal intercourse against the order of nature” with up to ten years’ imprisonment. It was introduced by British rulers in the nineteenth century.  
A challenge to section 377’s constitutionality was brought was brought before the Delhi High Court in 2001 by the Naz Foundation India, asking the court to declare the law should no longer apply to consenting adults. In response, the then government stated that “The purpose of section 377 of IPC is to provide a healthy environment in the society by criminalising unnatural sexual activities.” The case ended indecisively, and litigation is still pending.  
“Section 377 strikes at the basic right to privacy,” said Long. “This case shows how it is used against rights to free expression and to meeting in a public place. It casts a pall over public health efforts.”  
Human Rights Watch said that India’s constitution protects the right to equality, freedoms of speech and assembly and right to personal liberty. The International Covenant on Civil and Political Rights (ICCPR), to which India acceded in 1979, guarantees freedom from discrimination. In the case of Toonen v. Australia in 1994, the United Nations Human Rights Committee held these protections against discrimination in all areas of rights should be understood to include sexual orientation.

Source: India: Repeal Colonial-Era Sodomy Law (Human Rights Watch, 11-1-2006)

Posted in POZ Pages | Leave a Comment »

Treatment News : Fewer Side Effects with Videx/Epivir vs. Combivir

Posted by pozlife on March 1, 2007


Fewer Side Effects with Videx/Epivir vs. Combivir

by Tim Horn

A team of Spanish researchers is finding that, when combined with Sustiva® (efavirenz), Videx® EC (didanosine capsules) matched with Epivir® results in fewer treatment discontinuations due to side effects than Combivir® (zidovudine plus lamivudine).  The 24-week data from the 48-week GESIDA 3903 study also suggest that once-daily Sustiva/Videx/Epivir is comparable to Sustiva/Combivir with respect to viral load outcomes, with a possible CD4 cell count advantage.

According to the U.S. Department of Health and Human Services, in its Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents, only Combivir and Truvada (tenofovir plus emtricitabine) are considered “preferrednucleoside reverse transcriptase inhibitors (NRTIs) to combine with either a non-nucleoside reverse transcriptase inhibitor (NNRTI) or a protease inhibitor (PI) for HIV-positive patients starting therapy for the first time.  Videx EC combined with Epivir, prescribed separately but approved for once-daily use, is an “alternative” DHHS recommendation.  The reason for the more limited support of Videx EC and Epivir as a possible NRTI “backbone” to combine with suggested NNRTIs and PIs is a lack of data comparing this dual-NRTI combo to current leading NRTI pairings (e.g., Combivir).

GESIDA 3903 randomized 369 HIV-positive patients, none of whom had used antiretroviral therapy in the past, to Videx EC (400 mg) and Epivir (300 mg) once daily or Combivir twice daily, with both NRTI pairings taken with a standard dose of Sustiva (600 mg). 

The average viral load at study entry was 100,000 copies and the average CD4 count was approximately 210.  Approximately 7% of patients in the Videx/Epivir group and 3% of patients in the Combivir group had chronic hepatitis B virus infection; approximately 20% in both groups had active hepatitis C virus infection.

In the strict intent-to-treat analysis, which included everyone enrolled in the study even if they discontinued their treatment due to limited effectiveness or side effects, 71% of those in the Videx/Epivir group and 66% of those in the Combivir group had viral loads below 50 copies (undetectable) after 24 weeks.  In the more liberal on-treatment analysis, which only included the patients who completed 24 weeks of treatment, 82% of those in the Videx/Epivir group and 85% of those in the Combivir group had undetectable viral loads.

The differences between the two groups with respect to undetectable viral loads at week 24, in the intent-to-treat and on-treatment analysis, were not statistically significant, meaning they could have been due to chance.

CD4 count gains were significantly greater in the Videx/Epivir group compared to the Combivir group.  After 24 weeks, CD4 counts increased by an average of 128 cells (compared to study entry numbers) in the Videx/Epivir group, compared to a 110 CD4 cell count increase in the Combivir group.  This difference – along with differences in CD4 cell count increases at week 4 and 12 – were statistically significant. 

As for side effects, significantly more patients in the Combivir group (21%) discontinued treatment early due to side effects, compared to those in the Videx/Epivir group (13%).  Hematologic problems requiring treatment discontinuation, notably anemia and neutropenia, were much more common among those taking Combivir (6%) compared to Videx/EC (0.5%). 

There were no statistically significant differences between the two groups with respect to moderate-to-severe side effects like rash and central nervous system problems (caused by Sustiva), liver enzyme increases, or lipid (blood fat) level increases.

While these data are encouraging and support the use of Videx combined with Epivir as a worthy NRTI backbone pairing among patients starting therapy for the first time, the full 48-week data are required to draw any firm conclusions.


Berenguer J, Ribera E, Domingo P, et al. Didanosine, lamivudine, and efavirenz vs zidovudine, lamivudine, and efavirenz, for initial treatment of HIV infection: planned 24-week analysis of a prospective randomized non-inferiority clinical trial, GESIDA 39/03 [Abstract 504]. 14th Conference on Retroviruses and Opportunistic Infections, Los Angeles, 2007.

Source: POZ – Treatment News : Fewer Side Effects with Videx/Epivir vs. Combivir – by Tim Horn

Posted in POZ Pages | Leave a Comment »

Treatment News : Once-Daily Viramune Strikes Out

Posted by pozlife on March 1, 2007


Once-Daily Viramune Strikes Out

by Tim Horn

For several years, Boehringer Ingelheim and independent researchers have been looking into the possibility of once-daily Viramune® (nevirapine) dosing, to help simplify its use in the treatment of HIV.  However, new research presented at the 14th Conference on Retroviruses and Opportunistic Infections (CROI) suggests that the approved twice-daily schedule will remain the necessary dosing option, especially for those starting therapy with high viral loads, based on a significantly greater number of virologic failures seen in a French study comparing the two dosing schedules.

The DAUFIN study randomized 71 HIV-positive patients to one of two treatment groups.  In the first group, 36 patients took once-daily Viramune (400mg), Viread® (tenofovir; 245 mg), and Epivir® (lamivudine, 300 mg).  In the second group, 35 patients took twice-daily Viramune (200 mg) and Combivir® (zidovudine plus lamivudine).  All patients were treatment-naïve – new to treatment at the start of the study – and the men had to have CD4 counts below 350, whereas the women had to have CD4 counts below 250 (to reduce the risk of Viramune-related hypersensitivity). 

The average viral loads at study entry were 71,500 in the once-daily group and 80,282 in the twice-daily group.  Pre-treatment CD4 counts average 208 cells in both groups. 

The study began in May 2005, with a planned target enrollment of 250 patients.  However, by May of 2006, early virologic failure was documented in seven patients – all in the once-daily group – leading to early termination of the study.  The data presented at CROI reflected results for 71 patients enrolled in the trial before it was discontinued.

In total, eight individuals – again, all in the once-daily group – experienced early virologic failure, defined as a viral load that failed to drop more than 2 log by week 12 or a greater than 1 log rebound in viral load by week 12.  Two additional patients experienced virologic rebound later in the study, one in each study group.

It was not initially clear why patients in the once-daily group were much more likely to experience virologic failure compared to those in the twice-daily group.  Trough concentrations of Viramune – a measure of the drug in the blood – were somewhat lower in the once-daily group, but not significantly so. 

Two factors that did seem to play a role in early virologic failure were high viral loads and low CD4 counts at the time of study entry.  The average pre-treatment viral load among those who maintained virologic control was 51,189.  Among those who experienced virologic failure, the average pre-treatment viral load was 262,747.  As for pre-treatment CD4 cells, the average count among those who continued to respond well to treatment was 223, vs. an average pre-treatment count of 110 among those who experienced virologic failure.  These differences were statistically significant.

While discontinuation due to side effects was slightly more common among individuals in the twice-daily group compared to the once-daily group, the difference was not statistically significant.


Rey D, Schmitt MP, Hoizey G, et al. Early virologic non-response to once daily combination of lamivudine, tenofovir, and nevirapine in ART-naive HIV-infected patients: preliminary results of the DAUFIN study [Abstract 503]. 14th Conference on Retroviruses and Opportunistic Infections, Los Angeles, 2007.

Source: POZ – Treatment News : Once-Daily Viramune Strikes Out – by Tim Horn

Posted in POZ Pages | Leave a Comment »

Pirates of the Caribbean: Walking the Plank for HIV Care in Puerto Rico

Posted by pozlife on March 1, 2007


Pirates of the Caribbean: Walking the Plank for HIV Care in Puerto Rico

by Nicole Joseph

Jose F. Colon has spent the last six weeks fighting what he calls an “unbearable crisis” in the Puerto Rican AIDS community. The 54-year-old activist has met with local politicians. He has spoken to newspaper reporters. He even fasted for 33 hours. All from his bed at the Hospital Auxilio Mutuo in downtown San Juan.
“I decided to work from the hospital,” says Colon. As a sick man with both AIDS and diabetes, he says, the grim truth about Puerto Rico’s HIV care emergency has been staring him in the face. “I feel horrified. I feel like it’s 1980.”
You don’t need to check into the hospital to see that financial negligence and mismanagement are pushing Puerto Rico’s AIDS care to the brink. Earlier this month, two AIDS clinics shut down for lack of funds, cutting loose 1,500 HIV positive patients. An estimated 130 people are going without treatment on a waiting list and many more are in need; at least 10,000 Puerto Ricans are believed to be living with HIV.
But now a coalition of furious activists, including several groups from heavily Puerto Rican New York City, are saying enough is enough. They are insisting on federal action—or at least some acknowledgement of responsibility—and wondering whether a crisis of these proportions would be allowed to continue unchecked in any of the states on the U.S. mainland.
Puerto Rico, a U.S. “commonwealth territory” where locals are deeply divided over their relationship with Washington (many call for statehood instead or complete independence), got $58.4 million in HIV care funding last year from the federal Ryan White CARE Act. The average Puerto Rican is less and less likely to see those services, however. The funds’ distribution to local health clinics and Community Based Organizations (CBOs) has gotten painfully slow.
Funds or no funds, many clinics have stayed open anyway—sometimes without working bathrooms, telephones, air conditioning or adequate staff. Some have scraped together cash on their own and invoiced the Puerto Rico Department of Health and the San Juan AIDS Task Force. But with reimbursement now sometimes stretching to as many as nine months, more and more clinics have been forced to go out of business.
“This is something that has been going on for many years, but it has gotten critical in the last three,” says Anselmo Fonseca, co-founder and vice president of Pacientes de SIDA Pro Politica Sana. “Peoples’ lives are in danger, and too many key players either lack competence or…don’t give a damn.”
Last month, Fonseca and other local activists directly invited the feds to intervene. They sent a letter to the government official in charge of Ryan White distribution in Washington, DC: Dr. Deborah Parham Hopson, associate administrator of HIV/AIDS at the Health Resources and Services Administration (HRSA).
The activists recommended that a “third party” step in to dole out the money. The idea would be to put the funds in the hands of a “competent and trustworthy local agency such as the Puerto Rico Certified Public Accountants Chapter, or the office of a federal judgeship.”
In a statement to POZ, HRSA officials said that was one option among several they are considering, and that they are working in conjunction with the San Juan office of Mayor Jorge Santini to “improve the local situation as quickly as possible.”
Members of the New York-based Puerto Rican community who are monitoring the crisis hope that is exactly what’s in store—and have put their weight behind the request for federal help. The Latino Commission on AIDS (LCOA) wrote a second letter to Parham Hopson and also joined representatives of the National Minority AIDS Council and other groups at a February 9th meeting with the Congressional Hispanic Caucus in D.C. Then last week, the Caucus issued a third letter: this one to Michael O. Leavitt, Secretary of the U.S. Department of Health and Human Services, urging “prompt and decisive action to ensure that patients receive the care that Congress intended.”
The question is: How many more letters will be written before somebody steps up to the plate?
The situation is grave, with the CDC reporting that the island’s rate of infection for 2005 was 26.4 per 100,000, nearly twice the rate for the rest of the U.S. (Most Puerto Ricans are infected through injection drug use.)
“Our goal is to get HRSA to take this seriously,” says Dennis de Leon of the LCOA. “Some groups haven’t been paid in the last nine months —that part of the problem [will] be corrected whenever someone decides to correct it.”
This isn’t the first time Puerto Rican leaders have come under fire for mishandling AIDS money. In 1999 and 2000, several former officials of the San Juan AIDS institute were convicted of stealing more than $2 million of federal AIDS funds for personal and political gain. Last December, the FBI, the IRS and the Human Services Office of the Inspector General turned up the heat again by raiding several AIDS program offices in the municipality of San Juan, confiscating thousands of files and copying hard drives.
The San Juan division of the FBI declined to comment on what was found, or whether or not any charges will be filed, but advocates are concerned that the absence of those files might further delay the delivery of federal funds to the island’s increasingly needy CBOs.
To get directly involved, contact the LCOA.

Source: POZ – Special Reports : Pirates of the Caribbean: Walking the Plank for HIV Care in Puerto Rico – by Nicole Joseph

Posted in POZ Pages | Leave a Comment »

Meth + Protease Drugs = Danger

Posted by pozlife on November 29, 2006

How a chemical combo can lead to fatal consequences

By Bob Adams

Combining protease inhibitors with crystal meth can lead to meth overdoses. Protease drugs and meth are broken down by the same liver enzyme, researchers explain, but the enzyme works first on the anti-HIV medications. This allows meth to build up in the bloodstream to levels three to 10 times higher than if it were broken down immediately, which can lead to a potentially fatal overdose. The risks are especially high, researchers warn, with Norvir and Rescriptor.

How crystal meth changes the brain and leads to cognitive loss

Crystal methamphetamine can cause brain structure changes in HIV patients, leading to a higher risk of impaired cognitive functions, according to researchers at the University of California, San Diego. Brain scans showed that meth use increased the volume in portions of the brain linked with understanding one’s surroundings, motor function, and motivation. The greater the size increase, the more significant the loss of cognitive function. Because HIV itself can shrink other key parts of the brain that control thought, reasoning, memory, and learning, a combination of HIV infection and meth use could result in significant brain changes and greater chances for cognitive loss.

Posted in POZ Pages | Leave a Comment »